SOST and chronic kidney disease: FGF-23 is produced in multiple tissues, and it is likely—as seen in a report of sclerostin-independent extra-osseus FGF-23 production in patients with CKD—that extra-osseus production can also influence serum FGF-23 concentrations [40–43].